Drug Trial Radar · NCT02952508
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jul 26, 2017
Primary completion
Jun 22, 2026
Study completion Dec 22, 2027
Sponsor
- Lead sponsor
- Cellectar Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 2, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of iopofosine I 131 in patients with WM that have received at least two prior lines of therapy.
Conditions
- Waldenstrom Macroglobulinemia
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoplasmacytic Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Central Nervous System Lymphoma
Interventions
Iopofosine I 131 single doseDrug
Radiopharmaceutical
Iopofosine I 131 multiple doseDrug
Radiopharmaceutical
Iopofosine I 131 fractionated doseDrug
Radiopharmaceutical
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A [CLOVER-1] Clinical benefit rateTime frame: 84 days
- Part B [CLOVER-WaM] Major Response RateTime frame: 12 months
Locations
52 sites in 11 countries. Site status is shown where the registry gives one.
Cellectar Biosciences site
Los Angeles, California
Cellectar Biosciences site
Redlands, California
Cellectar Biosciences site
Washington D.C., District of Columbia
Cellectar Biosciences site
Jacksonville, Florida
Cellectar Biosciences site
Miami, Florida
Cellectar Biosciences site
Tampa, Florida
Cellectar Biosciences
Atlanta, Georgia
Cellectar Biosciences site
Maywood, Illinois
Cellectar Biosciences site
Warrenville, Illinois
Cellectar Biosciences site
Westwood, Kansas
Cellectar Biosciences site
New Orleans, Louisiana
Cellectar Biosciences site
Baltimore, Maryland
Cellectar Biosciences
Bethesda, Maryland
Cellectar Biosciences site
Boston, Massachusetts
Cellectar Biosciences
North Bergen, New Jersey
Cellectar Biosciences site
Buffalo, New York
Cellectar Biosciences site
New York, New York
Cellectar Biosciences site
Rochester, New York
Cellectar Biosciences site
Durham, North Carolina
Cellectar Biosciences
Canton, Ohio
Cellectar Biosciences site
Cincinnati, Ohio
Cellectar Biosciences Site
Charleston, South Carolina
Cellectar Biosciences
Greenville, South Carolina
Cellectar Biosciences site
Knoxville, Tennessee
Cellectar Biosciences site
Dallas, Texas
Cellectar Biosciences site
Dallas, Texas
Cellectar Biosciences site
Houston, Texas
Cellectar Biosciences site
Seattle, Washington
Cellectar Biosciences site
Madison, Wisconsin
Cellectar Biosciences site
Concord, New South Wales, Australia
Cellectar Biosciences
Adelaide, South Australia, Australia
Cellectar Biosciences
Salvador, Estado de Bahia, Brazil
Cellectar Biosciences
Curitiba, Paraná, Brazil
Cellectar Biosciences
Porto Alegre, RioGrande Do Sul, Brazil
Cellectar Biosciences
Blumenau, Santa Catarina, Brazil
Cellectar Biosciences Site
Hradec Králové, Czechia
Cellectar Biosciences
Helsinki, Finland
Cellectar Biosciences
Pessac, France
Cellectar Biosciences
Poitiers, France
Cellectar Biosciences site
Athens, Greece
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.